Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SMBYC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
mRG006
|
|||||
| Synonyms |
MRG006; MRG006A
Click to Show/Hide
|
|||||
| Organization |
Miracogen (Originator)
|
|||||
| Drug Status |
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-GPC3 mAb
|
Antibody Info | ||||
| Antigen Name |
Glypican-3 (GPC3)
|
Antigen Info | ||||
| Payload Name |
Novel TOP1 inhibitor
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
MCC-AAQ
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|